FMP

FMP

Enter

CAPR - Capricor Therap...

photo-url-https://financialmodelingprep.com/image-stock/CAPR.png

Capricor Therapeutics, Inc.

CAPR

NASDAQ

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

21.6 USD

2.02 (9.35%)

About

ceo

Dr. Linda Marbán Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, whic...

CIK

0001133869

ISIN

US14070B3096

CUSIP

14070B309

Address

10865 Road to the Cure

Phone

310 358 3200

Country

US

Employee

101

IPO Date

Feb 13, 2007

CAPR Financial Summary

CIK

0001133869

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

14070B309

ISIN

US14070B3096

Country

US

Price

21.6

Beta

4.03

Volume Avg.

2.61M

Market Cap

702.84M

Shares

-

52-Week

2.68-23.4

DCF

-12.88

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-24.27

P/B

-

Website

https://www.capricor.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CAPR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep